Phenotyping of CYP450 in human liver microsomes using the cocktail approach

Analytical and Bioanalytical Chemistry

Volumn 406, Issue 20, 2014, Pages 4875-4887

  Spaggiari, Dany ^a   Geiser, Laurent ^a   Daali, Youssef ^a   Rudaz, Serge ^a  

^a UNIVERSITY OF GENEVA   (Switzerland)

Author keywords

Cocktail approach; Cytochrome P450 profile; Genetic polymorphism; Human liver microsomes; Phenotyping; Ultra high pressure liquid chromatography quadrupole time of flight mass spectrometry

Indexed keywords

CHROMATOGRAPHY; ELECTROSPRAY IONIZATION; HIGH PRESSURE LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; PROBES;

COCKTAIL APPROACH; CYTOCHROME P450; GENETIC POLYMORPHISMS; HUMAN LIVER MICROSOMES; LIQUID CHROMATOGRAPHY-QUADRUPOLE TIME-OF-FLIGHT MASS SPECTROMETRIES; PHENOTYPING;

SUBSTRATES;

CYTOCHROME P-450 ENZYME SYSTEM; ISOENZYMES;

CHROMATOGRAPHY, LIQUID; DRUG DISCOVERY; ENZYMOLOGY; HUMANS; ISOTOPE LABELING; METABOLISM; METHODS; MICROSOMES, LIVER; MITOCHONDRIA, LIVER; PHENOTYPE; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; SUBSTRATE SPECIFICITY;

CHROMATOGRAPHY, LIQUID; CYTOCHROME P-450 ENZYME SYSTEM; DRUG DISCOVERY; HUMANS; ISOENZYMES; ISOTOPE LABELING; MICROSOMES, LIVER; MITOCHONDRIA, LIVER; PHENOTYPE; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; SUBSTRATE SPECIFICITY;

EID: 84904460876     PISSN: 16182642     EISSN: 16182650     Source Type: Journal    
DOI: 10.1007/s00216-014-7915-4     Document Type: Article

References (29)

1. Testa B, Pedretti A, Vistoli G (2012) Foundation review: reactions and enzymes in the metabolism of drugs and other xenobiotics. Drug Discov Today 17:549-560
2. Samer CF, Lorenzini KI, Rollason V, Daali Y, Desmeules JA (2013) Applications of CYP450 testing in the clinical setting. Mol Diagn Ther 17:165-184
3. Nicoli R, Curcio R, Rudaz S, Veuthey JL (2009) Development of an in-capillary approach to nanoscale automated in vitro cytochromes P450 assays. J Med Chem 52:2192-2195
4. Curcio R, Nicoli R, Rudaz S, Veuthey JL (2010) Evaluation of an in-capillary approach for performing quantitative cytochrome P450 activity studies. Anal Bioanal Chem 398:2163-2171
5. Tolonen A, Turpeinen M, Pelkonen A (2009) Liquid chromatography-mass spectrometry in in vitro drug metabolite screening. Drug Discov Today 14:120-133
6. Nicoli R, Martel S, Rudaz S, Wolfender JL, Veuthey JL, Carrupt PA, Guillarme D (2010) Advances in LC platforms for drug discovery. Expert Opin Drug Dis 5:475-489
7. Spaggiari D, Geiser L, Daali Y, Rudaz S (2014) A cocktail approach for assessing the in vitro activity of human cytochrome CYP450s: an overview of current methodologies. J Pharm Biomed Anal. doi: 10.1016/j.jpba.2014.03.018
8. Spaggiari D, Fekete S, Eugster PJ, Veuthey JL, Geiser L, Rudaz S, Guillarme D (2013) Contribution of various types of liquid chromatography-mass spectrometry instruments to band broadening in fast analysis. J Chromatogr A 1310:45-55
9. Matuszewski BK, Constanzer ML, Chavez-Eng CM (2003) Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS. Anal Chem 75:3019-3030
10. Yuan R, Madani S, Wei XX, Reynolds K, Huang SM (2002) Evaluation of cytochrome P450 probe substrates commonly used by the pharmaceutical industry to study in vitro drug interactions. Drug Metab Dispos 30:1311-1319
11. Jerdi MC, Daali Y, Oestreicher MK, Cherkaoui S, Dayer P (2004) A simplified analytical method for a phenotyping cocktail of major CYP450 biotransformation routes. J Pharm Biomed Anal 35:1203-1212
12. Bosilkovska M, Déglon J, Samer C, Walder B, Desmeules J, Staub C, Daali Y (2014) Simultaneous LC-MS/MS quantification of P-glycoprotein and cytochrome P450 probe substrates and their metabolites in DBS and plasma. Bioanalysis 6:151-164
13. Watanabe A, Nakamura K, Okudaira N, Okazaki O, Sudo KI (2007) Risk assessment for drug-drug interaction caused by metabolism-based inhibition of CYP3A using automated in vitro assay systems and its application in the early drug discovery process. Drug Metab Dispos 35:1232-1238
14. Sevrioukova IF, Poulos TL (2013) Understanding the mechanism of cytochrome P450 3A4: recent advances and remaining problems. Dalton Trans 42:3116-3126
15. Tucker GT, Houston JB, Huang SM (2001) Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential - towards a consensus. Br J Clin Pharmacol 52:107-117
16. Bjornsson TD, Callaghan JT, Einolf HJ, Fischer V, Gan L, Grimm S, Kao J, King SP, Miwa G, Ni L, Kumar G, McLeod J, Obach RS, Roberts S, Roe A, Shah A, Snikeris F, Sullivan JT, Tweedie D, Vega JM, Walsh J, Wrighton SA (2003) The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. Drug Metab Dispos 31:815-832
17. Di L, Kerns EH, Li SQ, Carter GT (2007) Comparison of cytochrome P450 inhibition assays for drug discovery using human liver microsomes with LC-MS, rhCYP450 isozymes with fluorescence, and double cocktail with LC-MS. Int J Pharm 335:1-11
18. Walsky RL, Obach RS (2004) Validated assays for human cytochrome P450 activities. Drug Metab Dispos 32:647-660
19. Weaver R, Graham KS, Beattie IG, Riley RJ (2003) Cytochrome P450 inhibition using recombinant proteins and mass spectrometry/multiple reaction monitoring technology in a cassette incubation. Drug Metab Dispos 31:955-966
20. Kozakai K, Yamada Y, Oshikata M, Kawase T, Suzuki E, Haramaki Y, Taniguchi H (2012) Reliable high-throughput method for inhibition assay of 8 cytochrome P450 isoforms using cocktail of probe substrates and stable isotope-labeled internal standards. Drug Metab Pharmacokinet 27:520-529
21. US Food and Drug Administration (2011) Drug development and drug interactions: table of substrates, inhibitors and inducers. http://www.fda.gov/ drugs/developmentapprovalprocess/developmentresources/druginteractionslabeling/ ucm093664.htm. Accessed Jan 2014
22. Chauret N, Gauthier A, Nicoll-Griffith DA (1998) Effect of common organic solvents on in vitro cytochrome P450-mediated metabolic activities in human liver microsomes. Drug Metab Dispos 26:1-4
23. Baudoin R, Prot JM, Nicolas G, Brocheton J, Brochot C, Legallais C, Benech H, Leclerc E (2013) Evaluation of seven drug metabolisms and clearances by cryopreserved human primary hepatocytes cultivated in microfluidic biochips. Xenobiotica 43:140-152
24. Palmer JL, Scott RJ, Gibson A, Dickins M, Pleasance S (2001) An interaction between the cytochrome P450 probe substrates chlorzoxazone (CYP2E1) and midazolam (CYP3A). Br J Clin Pharmacol 52:555-561
25. Pillai VC, Strom SC, Caritis SN, Venkataramanan R (2013) A sensitive and specific CYP cocktail assay for the simultaneous assessment of human cytochrome P450 activities in primary cultures of human hepatocytes using LC-MS/MS. J Pharm Biomed Anal 74:126-132
26. Dierks EA, Stams KR, Lim HK, Cornelius G, Zhang HL, Ball SE (2001) A method for the simultaneous evaluation of the activities of seven major human drug-metabolizing cytochrome P450s using an in vitro cocktail of probe substrates and fast gradient liquid chromatography tandem mass spectrometry. Drug Metab Dispos 29:23-29
27. Wilson ZE, Rostami-Hodjegan A, Burn JL, Tooley A, Boyle J, Ellis SW, Tucker GT (2003) Inter-individual variability in levels of human microsomal protein and hepatocellularity per gram of liver. Br J Clin Pharmacol 56:433-440
28. Guengerich FP (2008) Cytochrome P450 and chemical toxicology. Chem Res Toxicol 21:70-83
29. Patki KC, von Moltke LL, Greenblatt DJ (2003) In vitro metabolism of midazolam, triazolam, nifedipine, and testosterone by human liver microsomes and recombinant cytochromes P450: role of CYP3A4 and CYP3A5. Drug Metab Dispos 31:938-944